## Management of Suboptimal Glycemic Control on Monotherapy **Key Point:** When a patient on metformin monotherapy fails to achieve target HbA1c (typically <7%), the guideline-recommended next step is addition of a second agent rather than maximizing a single drug or jumping to insulin. ### Rationale for Adding a Second Agent This patient has: - HbA1c 9.2% (target typically 7–8% in most type 2 DM patients) - Inadequate response to metformin 1000 mg BD (standard therapeutic dose) - No contraindications to oral agents (no DKA, normal renal function implied) - Symptomatic hyperglycemia requiring intervention **High-Yield:** The stepwise approach to type 2 DM management follows a clear algorithm: 1. Lifestyle modification 2. Metformin monotherapy 3. **Add second agent** (sulfonylurea, DPP-4 inhibitor, GLP-1 agonist, SGLT-2 inhibitor, or thiazolidinedione) 4. Triple therapy 5. Insulin ± oral agents ### Why Each Option Fits or Fails | Step | Indication | Status in This Case | |------|-----------|---------------------| | Maximize metformin | Dose <1000 mg BD | Already at standard dose | | **Add second agent** | **HbA1c >7.5% on monotherapy** | **✓ CORRECT** | | Switch to insulin | Failure of 2–3 agents or acute decompensation | Premature; only on one agent | | Observe 3 months | Newly diagnosed or recent dose change | Not appropriate; patient symptomatic | **Clinical Pearl:** Combination therapy with agents having different mechanisms (e.g., metformin + sulfonylurea or metformin + DPP-4 inhibitor) provides additive glycemic benefit and reduces the risk of monotherapy resistance. **Tip:** In NEET PG exams, recognize that insulin is reserved for: - Failure of oral combination therapy (2–3 agents) - Acute metabolic decompensation (DKA, HHS) - Pregnancy - Severe renal or hepatic impairment - Acute illness or surgery This patient is in the **stepwise escalation phase**, not yet at insulin indication.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.